Faeth Therapeutics to Participate in the Stifel 2023 Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)-- Faeth Therapeutics, an oncology company with clinical programs combining therapeutics with metabolic optimization to achieve greater efficacy, today announced that the company will be participating in a company presentation and 1x1 investor meetings at the Stifel 2023 Healthcare Conference, taking place from November 14-15 in New York City.

Anand Parikh, J.D., Chief Executive Officer & Co-Founder, Oliver Maddocks, PhD, Head of Research & Co-Founder, and Debbie Chirnomas, MD, Chief Medical Officer, will present a company overview on Wednesday, November 15, at 3:00 pm ET.

About Faeth Therapeutics

Faeth Therapeutics, headquartered in Austin, TX, is a clinical-stage biotechnology company focused on bringing breakthrough research in metabolic oncology into the clinic. The company leverages its machine-learning platform to develop precision therapies, augmented by a metabolic regimen involving the patient’s diet, to revolutionize the treatment paradigm. Faeth’s lead program combines FTH-001, serabelisib, with FTH-003, sapanisertib, and an insulin suppressing regimen to slow tumor growth by shutting down the PI3K/mTOR pathway. Faeth’s scientific founders include industry leaders Drs. Lew Cantley, Sid Mukherjee, Karen Vousden. For additional information, visit www.faeththerapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231108801167/en/

Investor Contact
Jessi Vo
Gilmartin Group
[email protected]

Media Contact
Dominic Johnson
Consort Partners
[email protected]

Source: Faeth Therapeutics

You May Also Be Interested In

• SES’s Final Three O3b mPOWER Satellites Successfully Launched
• Glenfarne Group Promotes Oliver Wood to Global Head of Projects
• Bitcoin Price Prediction: BTC Golden Cross Targets $90K as $2.64M Sits in AlphaPepe Before Price Discovery